To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.
Early disease and low baseline damage predict response to belimumab in patients with systemic lupus erythematosus
Gatto, Mariele;Saccon, Francesca;Zen, Margherita;Tincani, Angela;Bortoluzzi, Alessandra;Piga, Matteo;Vacca, Angelo;Gerli, Roberto;Larosa, Maddalena;Iaccarino, Luca;Doria, Andrea
2020
Abstract
To investigate predictors of response, remission, low disease activity (LDA), damage and drug discontinuation in patients with systemic lupus erythematosus (SLE) treated with belimumab.File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
